JAK1 and graft versus host disease: Since ruxolitinib suppresses the JAK1/2 dependent cytokine response, we hypothesized that ruxolitinib might attenuate the cytokine mediated inflammatory tissue damage in GvHD and thus might favorably affect the severity and course of GvHD after allo-HCT.